Screening for ovarian cancer

Clinical Obstetrics and Gynecology

Volumn 49, Issue 3, 2006, Pages 433-447

  Rosenthal, Adam N ^a   Menon, Usha ^a   Jacobs, Ian J ^a  

^a Napolitano and Prof David)   (United Kingdom)

Author keywords

Ovarian cancer; Screening; Serum markers; Ultrasound

Indexed keywords

CA 125 ANTIGEN;

ALGORITHM; CANCER CYTODIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE MARKER; DOPPLER ECHOGRAPHY; FAMILIAL CANCER; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MASS SPECTROMETRY; MEDICAL EXAMINATION; OVARY CANCER; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SCREENING TEST; SURVIVAL RATE; SURVIVAL TIME; THREE DIMENSIONAL IMAGING; TRANSVAGINAL ECHOGRAPHY; VAGINA;

FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; PHYSICAL EXAMINATION; TUMOR MARKERS, BIOLOGICAL; UTERUS;

EID: 33746829487     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200609000-00004     Document Type: Review

References (62)

1. United States Cancer Statistics 2002 Incidence and Mortality (published 2005). http://seer.cancer.gov/csr/1975_2002/results_single/sect_01_table.01.pdf.
2. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol. 2003;189:1120-1127.
3. FIGO (International Federation of Gynecology and Obstetrics). Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2003;83(Suppl 1):ix-xxii, 1-229.
4. http://www.ukctocs.org.uk/
5. Buys SS, Partridge E, Greene MH, et al. PLCO Project Team. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomised trial. Am J Obstet Gynecol. 2005;193:1630-1639.
6. Jacobs I, Oram D. Screening for ovarian cancer. Biomed Pharmacother. 1988;42:589-596.
7. Bast RC Jr, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331-1337.
8. Zurawski VR Jr, Knapp RC, Einhorn N, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30:7-14.
9. Zurawski VR Jr, Orjaseter H, Andersen A, et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia; relevance for early detection of ovarian cancer. Int J Cancer. 1988;42:677-680.
10. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
11. Silberstein LB, Rosenthal AN, Coppack SW, et al. Ascites and a raised serum CA 125-confusing combination. J Royal Soc Med. 2001;94:581-582.
12. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353:1207-1210.
13. Skates SJ, Menon U, MacDonald N, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003;21(10 Suppl):206-210.
14. Menon U, Skates SJ, Lewis S, et al. A prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005;23:7919-7926.
15. Menon U, Jacobs IJ. Tumour markers and screening. In: Berek JS, Hacker NF, Eds. Chapter 2 in Practical Gynaecologic Oncology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005; 43-66.
16. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
17. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 2003;4:24.
18. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics. 2004;3:367-378.
19. Villanueva J, Philip J, Entenberg D, et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem. 2004;76:1560-1570.
20. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882-5890.
21. Ye B, Cramer DW, Skates SJ, et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res. 2003;9:2904-2911.
22. Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for ovarian cancer. Brit Med J. 1989;299:1363-1367.
23. DePriest PD, Shenson D, Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol. 1993;51:7-11.
24. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003;102:594-599.
25. Kurjak A, Schulman H, Sosic A, et al. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol. 1992;80:917-921.
26. Einhorn N, Sjovall K, Knapp RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14-18.
27. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Brit Med J. 1996;313:1355-1358.
28. Adonakis GL, Paraskevaidis E, Tsiga S, et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol. 1996;65:221-225.
29. Grover S, Quinn MA, Weidman P, et al. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. Int J Gynecol Cancer. 1995;5:291-295.
30. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77:350-356.
31. Sato S, Yokoyama Y, Sakamoto T, et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer. 2000;89:582-588.
32. Hayashi H, Yaginuma Y, Kitamura S, et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol Obstet Invest. 1999;47:58-64.
33. Tabor A, Jensen FR, Bock JE, et al. Feasibility study of a randomised trial of ovarian cancer screening. J Med Screen. 1994;1:215-219.
34. Millo R, Facca MC, Alberico S. Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer? Clin Exp Obstet Gynecol. 1989;16:72-78.
35. Goswamy RK, Campbell S, Whitehead MI. Screening for ovarian cancer. Clin Obstet Gynaecol. 1983;10:621-643.
36. Kurjak A, Kupesic S. Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Ultrasound Obstet Gynecol. 1995;6:145-159.
37. Vuento MH, Pirhonen JP, Makinen JI, et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer. 1995;76:1214-1218.
38. Parkes CA, Smith D, Wald NJ, et al. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen. 1994;1:209-214.
39. Holbert TR. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am J Obstet Gynecol. 1994;170:1699-1703.
40. Beral V, Fraser P, Chilvers C. Does pregnancy protect against ovarian cancer? Lancet. 1978;1:1083-1087.
41. Schwartz M, Lerman C, Daly M, et al. Utilization of ovarian cancer screening by women at increased risk. Cancer Epidemiol Biomarkers Prev. 1995;4:269-273.
42. Kew FM, Ashton VJ, Cruickshank DJ. Tolerability of transvaginal ultrasonography as an ovarian cancer screening test. J Med Screen. 2004;11:45-47.
43. Drescher CW, Nelson J, Peacock S, et al. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening. Cancer Epidemiol Biomarkers Prev. 2004;13:600-606.
44. Hogg R, Friedlander M. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol. 2004;22:1315-1327.
45. Jacobs IJ. Screening for familial ovarian cancer: the need for well-designed prospective studies. J Clin Oncol. 2005;23:5443-5445.
46. Weiner Z, Beck D, Shteiner M, et al. Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J Ultrasound Med. 1993;12:387-393.
47. Muto MG, Cramer DW, Brown DL, et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol. 1993;51:12-20.
48. Belinson JL, Okin C, Casey G, et al. The familial ovarian cancer registry: progress report. Cleve Clin J Med. 1995;62:129-134.
49. Menkiszak J, Jakubowska A, Gronwald J, et al. Hereditary ovarian cancer: summary of 5 years of experience [Polish]. Ginekol Pol. 1998;69:283-287.
50. Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design, and early results. Am J Obstet Gynecol. 1993;169:494-501.
51. Karlan BY, Baldwin RL, Lopez-Luevanos E, et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol. 1999;180:917-928.
52. Dorum A, Kristensen GB, Abeler VM, et al. Early detection of familial ovarian cancer. Eur J Cancer. 1996;32A:1645-1651.
53. Dorum A, Heimdal K, Lovslett K, et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand. 1999;78:906-911.
54. Taylor KJ, Schwartz PE. Cancer screening in a high risk population: a clinical trial. Ultrasound Med Biol. 2001;27:461-466.
55. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol. 2002;20:1260-1268.
56. Laframboise S, Nedelcu R, Murphy J, et al. Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer. 2002;12:86-91.
57. Liede A, Karlan BY, Baldwin RL, et al. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002;20:1570-1577.
58. Tailor A, Bourne TH, Campbell S, et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol. 2003;21:378-385.
59. Fries MH, Hailey BJ, Flanagan J, et al. Outcome of five years of accelerated surveillance in patients at high risk for inherited breast/ovarian cancer: report of a phase II trial. Mil Med. 2004;169:411-416.
60. Stirling D, Evans DG, Pichert G, et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early FIGO stage. J Clin Oncol. 2005;23:5588-5596.
61. Olivier RI, Lubsen-Brandsma MA, Verhoef S, et al. CA125 and transvaginal ultrasound monitoring in highrisk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006;100:20-26.
62. Urban N, Drescher C, Etzioni R, et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 1997;18:251-270.